Home Cart Sign in  
Chemical Structure| 128796-39-4 Chemical Structure| 128796-39-4

Structure of 128796-39-4

Chemical Structure| 128796-39-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Synonyms: 4-Trifluoromethylphenylboronic acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Wen Ren ; Yuling Deng ; Jacob D. Ward ; Rebecca Vairin ; Ruoli Bai b ; Hashini I. Wanniarachchi , et al.

Abstract: The synthesis and evaluation of small-molecule inhibitors of tubulin polymerization remains a promising approach for the development of new therapeutic agents for cancer treatment. The natural products colchicine and combretastatin A-4 (CA4) inspired significant drug discovery campaigns targeting the colchicine site located on the beta-subunit of the tubulin heterodimer, but so far these efforts have not yielded an approved drug for cancer treatment in human patients. Interest in the colchicine site was enhanced by the discovery that a subset of colchicine site agents demonstrated dual functionality as both potent antiproliferative agents and effective vascular disrupting agents (VDAs). Our previous studies led to the discovery and development of a 2-aryl-3-aroyl-indole analogue (OXi8006) that inhibited tubulin polymerization and demonstrated low nM IC50 values against a variety of human cancer cell lines. A water-soluble phosphate prodrug salt (OXi8007), synthesized from OXi8006, displayed promising vascular disrupting activity in mouse models of cancer. To further extend structure-activity relationship correlations, a series of 6-aryl-3-aroyl-indole analogues was synthesized and evaluated for their inhibition of tubulin polymerization and cytotoxicity against human cancer cell lines. Several structurally diverse molecules in this small library were strong inhibitors of tubulin polymerization and of MCF-7 and MDA-MB-231 human breast cancer cells. One of the most promising analogues (KGP591) caused significant G2/M arrest of MDA-MB-231 cells, disrupted microtubule structure and cell morphology in MDA-MB-231 cells, and demonstrated significant inhibition of MDA-MB-231 cell migration in a wound healing (scratch) assay. A phosphate prodrug salt, KGP618, synthesized from its parent phenolic precursor, KGP591, demonstrated significant reduction in bioluminescence signal when evaluated in vivo against an orthotopic model of kidney cancer (RENCA-luc) in BALB/c mice, indicative of efficacy. The most active compounds from this series offer promise as anticancer therapeutic agents.

Keywords: Inhibitors of tubulin polymerization ; Vascular disrupting agents ; synthesis ; Molecular docking ; Antiproliferative agents ; Inhibitors of cell migration

Purchased from AmBeed: ; ; ; ; ; 64-86-8 ; ; ; ; ; ; ; ; 4521-61-3 ; 4521-61-3 ; 87199-18-6 ; 64-86-8 ; 64-86-8 ; 128796-39-4 ; 5720-05-8 ; 64-86-8

Guo, Sheng ; Wu, Yifan ; Luo, Shao-Xiong Lennon ; Swager, Timothy M. ;

Abstract: Heterogenous catalysts with confined nanoporous catalytic sites are shown to have high activity and size selectivity. A solution-processable nanoporous organic polymer (1-BPy-Pd) catalyst displays high catalytic performance (TON > 200K) in the heterogeneous Suzuki–Miyaura coupling (SMC) reaction and can be used for the preparation of the intermediates in the synthesis of pharmaceutical agents. In comparison to the homogeneous catalyst analogue (2,2′-BPy)PdCl2, the heterogenous system offers size-dependent catalytic activity when bulkier substrates are used. Furthermore, the catalyst can be used to create catalytic impellers that simplify its use and recovery. We found that this system also works for applications in heterogenous Heck and nitroarenes reduction reactions. The metal-binding nanoporous polymer reported here represents a versatile platform for size-selective heterogeneous and recyclable catalysts.

Keywords: nanoporous organic polymer ; heterogeneous catalyst ; Suzuki−Miyaura coupling reaction ; size-selective reaction ; catalyst processing

Alternative Products

Product Details of [ 128796-39-4 ]

CAS No. :128796-39-4
Formula : C7H6BF3O2
M.W : 189.93
SMILES Code : FC(C1=CC=C(B(O)O)C=C1)(F)F
Synonyms :
4-Trifluoromethylphenylboronic acid
MDL No. :MFCD00151855
InChI Key :ALMFIOZYDASRRC-UHFFFAOYSA-N
Pubchem ID :2734389

Safety of [ 128796-39-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 128796-39-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 6
Fraction Csp3 0.14
Num. rotatable bonds 2
Num. H-bond acceptors 5.0
Num. H-bond donors 2.0
Molar Refractivity 41.27
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

40.46 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.71
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.54
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.37
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.29
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.98

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.3
Solubility 0.942 mg/ml ; 0.00496 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.18
Solubility 1.27 mg/ml ; 0.00668 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.18
Solubility 1.26 mg/ml ; 0.00665 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.24 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.57

Application In Synthesis of [ 128796-39-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 128796-39-4 ]
  • Downstream synthetic route of [ 128796-39-4 ]

[ 128796-39-4 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 3132-99-8 ]
  • [ 128796-39-4 ]
  • [ 343604-24-0 ]
References: [1] Patent: WO2005/118542, 2005, A1, . Location in patent: Page/Page column 45-46.
[2] ChemMedChem, 2016, p. 2194 - 2204.
[3] Archiv der Pharmazie, 2005, vol. 338, # 1, p. 9 - 17.
[4] Pharmazie, 2003, vol. 58, # 12, p. 854 - 856.
[5] Organic Letters, 2011, vol. 13, # 5, p. 952 - 955.
[6] Angewandte Chemie - International Edition, 2018, vol. 57, # 17, p. 4622 - 4626[7] Angew. Chem., 2018, vol. 130, # 17, p. 4712 - 4716,5.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 128796-39-4 ]

Fluorinated Building Blocks

Chemical Structure| 1423-26-3

A437948 [1423-26-3]

(3-(Trifluoromethyl)phenyl)boronic acid

Similarity: 1.00

Chemical Structure| 73852-19-4

A200674 [73852-19-4]

(3,5-Bis(trifluoromethyl)phenyl)boronic acid

Similarity: 0.98

Chemical Structure| 1423-27-4

A144870 [1423-27-4]

(2-Trifluoromethyl)phenylboronic acid

Similarity: 0.96

Chemical Structure| 864759-67-1

A319925 [864759-67-1]

(3-Methyl-4-(trifluoromethyl)phenyl)boronic acid

Similarity: 0.96

Chemical Structure| 947533-94-0

A375037 [947533-94-0]

(4-Methyl-3-(trifluoromethyl)phenyl)boronic acid

Similarity: 0.96

Organoborons

Chemical Structure| 1423-26-3

A437948 [1423-26-3]

(3-(Trifluoromethyl)phenyl)boronic acid

Similarity: 1.00

Chemical Structure| 73852-19-4

A200674 [73852-19-4]

(3,5-Bis(trifluoromethyl)phenyl)boronic acid

Similarity: 0.98

Chemical Structure| 1423-27-4

A144870 [1423-27-4]

(2-Trifluoromethyl)phenylboronic acid

Similarity: 0.96

Chemical Structure| 864759-67-1

A319925 [864759-67-1]

(3-Methyl-4-(trifluoromethyl)phenyl)boronic acid

Similarity: 0.96

Chemical Structure| 947533-94-0

A375037 [947533-94-0]

(4-Methyl-3-(trifluoromethyl)phenyl)boronic acid

Similarity: 0.96

Aryls

Chemical Structure| 1423-26-3

A437948 [1423-26-3]

(3-(Trifluoromethyl)phenyl)boronic acid

Similarity: 1.00

Chemical Structure| 73852-19-4

A200674 [73852-19-4]

(3,5-Bis(trifluoromethyl)phenyl)boronic acid

Similarity: 0.98

Chemical Structure| 1423-27-4

A144870 [1423-27-4]

(2-Trifluoromethyl)phenylboronic acid

Similarity: 0.96

Chemical Structure| 864759-67-1

A319925 [864759-67-1]

(3-Methyl-4-(trifluoromethyl)phenyl)boronic acid

Similarity: 0.96

Chemical Structure| 947533-94-0

A375037 [947533-94-0]

(4-Methyl-3-(trifluoromethyl)phenyl)boronic acid

Similarity: 0.96

Trifluoromethyls

Chemical Structure| 1423-26-3

A437948 [1423-26-3]

(3-(Trifluoromethyl)phenyl)boronic acid

Similarity: 1.00

Chemical Structure| 73852-19-4

A200674 [73852-19-4]

(3,5-Bis(trifluoromethyl)phenyl)boronic acid

Similarity: 0.98

Chemical Structure| 1423-27-4

A144870 [1423-27-4]

(2-Trifluoromethyl)phenylboronic acid

Similarity: 0.96

Chemical Structure| 864759-67-1

A319925 [864759-67-1]

(3-Methyl-4-(trifluoromethyl)phenyl)boronic acid

Similarity: 0.96

Chemical Structure| 947533-94-0

A375037 [947533-94-0]

(4-Methyl-3-(trifluoromethyl)phenyl)boronic acid

Similarity: 0.96